These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34830933)

  • 81. ZCCHC3 and Efp coordinately contribute to the pathophysiology of triple-negative breast cancer by modulating NCAPH.
    Fujimoto A; Ikeda K; Takeiwa T; Osaki A; Horie K; Inoue S
    Biochem Biophys Res Commun; 2024 Nov; 735():150663. PubMed ID: 39276521
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.
    Sester S; Wilms G; Ahlburg J; Babendreyer A; Becker W
    BMC Cancer; 2024 Oct; 24(1):1341. PubMed ID: 39482615
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hepatic Dyrk1b impairs systemic glucose homeostasis by modulating Wbp2 expression in a kinase activity-dependent manner.
    Li L; Zou Y; Shen C; Chen N; Tong M; Liu R; Wang J; Ning G
    Heliyon; 2024 Sep; 10(17):e36726. PubMed ID: 39296215
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.
    Kokkorakis N; Zouridakis M; Gaitanou M
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675189
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients.
    Almohaywi M; Sugita BM; Centa A; Fonseca AS; Antunes VC; Fadda P; Mannion CM; Abijo T; Goldberg SL; Campbell MC; Copeland RL; Kanaan Y; Cavalli LR
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685851
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A novel coiled-coil domain containing-related gene signature for predicting prognosis and treatment effect of breast cancer.
    Wang Y; Wang Y; Zhou J; Ying P; Wang Z; Wu Y; Hao M; Qiu S; Jin H; Wang X
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14205-14225. PubMed ID: 37558766
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Quiescent Cancer Cells-A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse.
    Lindell E; Zhong L; Zhang X
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835173
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer.
    Zhang L; Xie G; Xiao X; Cheng C
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3835-3846. PubMed ID: 35997823
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells.
    Chang CC; Chiu CC; Liu PF; Wu CH; Tseng YC; Lee CH; Shu CW
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830933
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.
    Tzeng YT; Liu PF; Li JY; Liu LF; Kuo SY; Hsieh CW; Lee CH; Wu CH; Hsiao M; Chang HT; Shu CW
    Front Pharmacol; 2018; 9():1285. PubMed ID: 30473665
    [No Abstract]   [Full Text] [Related]  

  • 91. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing.
    Yoo TK; Lee WS; Kim J; Kim MK; Park IA; Kim JH; Han W
    J Breast Cancer; 2022 Jun; 25(3):164-177. PubMed ID: 35657000
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.
    Sanz-Álvarez M; Cristóbal I; Luque M; Santos A; Zazo S; Madoz-Gúrpide J; Caramés C; Chiang CM; García-Foncillas J; Eroles P; Albanell J; Rojo F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809005
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.